<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955461</url>
  </required_header>
  <id_info>
    <org_study_id>C66-07-F</org_study_id>
    <nct_id>NCT00955461</nct_id>
  </id_info>
  <brief_title>Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System</brief_title>
  <official_title>Post-Market, Randomized, Single Blind, Split-Faced Comparison of the RevLite Nd:YAG Laser System Versus a Non-Ablative, Mid Infra-red, Fractionated Type Laser System for Skin Rejuvenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConBio, a Cynosure Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the results of treatment between the side of the face&#xD;
      treated with the RevLite Laser and the side of the face treated with a fractionated laser&#xD;
      system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the percentage of overall, cumulative improvement from Baseline in the appearance of wrinkles, skin tone and/or texture, pigmentation and acne scars</measure>
    <time_frame>3 and 6 months post final treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Photodamage</condition>
  <condition>Irregular Pigmentation</condition>
  <condition>Acne Scars</condition>
  <arm_group>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RevLite laser treatment</intervention_name>
    <description>Electro-optic Q-Switched Nd: YAG Laser treatment</description>
    <arm_group_label>Laser treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fractionated Laser treatment</intervention_name>
    <arm_group_label>Laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fitzpatrick Skin Type I-VI and Wrinkle Class I&#xD;
&#xD;
          -  Between the ages of 25-65&#xD;
&#xD;
          -  Evidence of bilateral dyschromia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, lactating, or is planning to become pregnant&#xD;
&#xD;
          -  history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or&#xD;
             photodermatosis&#xD;
&#xD;
          -  any skin pathology/condition that could interfere with evaluation or requires the use&#xD;
             of interfering topical or systemic therapy&#xD;
&#xD;
          -  coagulation disorder or currently using anti-coagulation medication (including but not&#xD;
             limited to heavy aspirin therapy)&#xD;
&#xD;
          -  any condition which, in the investigator's opinion, would make it unsafe for the&#xD;
             subject to participate in the study&#xD;
&#xD;
          -  currently enrolled in an investigational drug or device trial, or has received an&#xD;
             investigational drug or been treated with an investigational device within 30 days&#xD;
&#xD;
          -  unable to communicate or cooperate with the investigator due to language problems,&#xD;
             poor mental development, or impaired cerebral function&#xD;
&#xD;
          -  unreliable for the study, including subjects who engage in excessive alcohol intake or&#xD;
             drug abuse, or subjects who are unable to return for scheduled follow-up visits&#xD;
&#xD;
          -  Accutane within 6 months&#xD;
&#xD;
          -  need to be exposed to artificial tanning devices or excessive sunlight during the&#xD;
             trial&#xD;
&#xD;
          -  prior treatment with parenteral gold therapy&#xD;
&#xD;
          -  Diabetes Type 1 or 2&#xD;
&#xD;
          -  does not agree to refrain from any other type of facial skin resurfacing (e.g.,&#xD;
             microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other&#xD;
             substances (e.g., Restylane, Botox) that might affect the treatment area for the&#xD;
             duration of the study&#xD;
&#xD;
          -  artificial tanning within 1 month&#xD;
&#xD;
          -  (micro)dermabrasion within 3 months&#xD;
&#xD;
          -  other laser or IPL to the face within 6 months&#xD;
&#xD;
          -  chemical peel within 1 month&#xD;
&#xD;
          -  injectable fillers within 3 months&#xD;
&#xD;
          -  topical retinoids within 3 months&#xD;
&#xD;
          -  over-the-counter anti-aging products (e.g., those containing peptides, hyaluronic&#xD;
             acid, or agents specifically advertised as having anti-aging or age-inhibiting&#xD;
             properties) within 1 month&#xD;
&#xD;
          -  history of keloids or hypertrophic scarring&#xD;
&#xD;
          -  evidence of compromised wound healing&#xD;
&#xD;
          -  history of cold sores, chickenpox or shingles and unwilling to take a prophylactic&#xD;
             course of Valtrex/acyclovir&#xD;
&#xD;
          -  allergy to acyclovir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Sadick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sadick Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

